GLP1R and lung carcinoma: The associations between the treatment durations of three relatively new classes of antidiabetic medications, namely glucagon-like peptide-1 receptor agonists (GLP-1RA), dipeptidyl peptidase 4 inhibitors (DPP-4I), and sodium–glucose cotransporter 2 inhibitors (SGLT-2I), and lung cancer prognosis remain unclear.